Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 11

1.

The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.

Bisaga A, Sullivan MA, Glass A, Mishlen K, Pavlicova M, Haney M, Raby WN, Levin FR, Carpenter KM, Mariani JJ, Nunes EV.

Drug Alcohol Depend. 2015 Sep 1;154:38-45. doi: 10.1016/j.drugalcdep.2015.05.013. Epub 2015 Jul 8.

PMID:
26187456
2.

Is cannabis use associated with less opioid use among people who inject drugs?

Kral AH, Wenger L, Novak SP, Chu D, Corsi KF, Coffa D, Shapiro B, Bluthenthal RN.

Drug Alcohol Depend. 2015 Aug 1;153:236-41. doi: 10.1016/j.drugalcdep.2015.05.014. Epub 2015 May 22.

PMID:
26051162
3.

Can cannabis be considered a substitute medication for alcohol?

Subbaraman MS.

Alcohol Alcohol. 2014 May-Jun;49(3):292-8. doi: 10.1093/alcalc/agt182. Epub 2014 Jan 8. Review.

4.

Impact of cannabis use during stabilization on methadone maintenance treatment.

Scavone JL, Sterling RC, Weinstein SP, Van Bockstaele EJ.

Am J Addict. 2013 Jul-Aug;22(4):344-51. doi: 10.1111/j.1521-0391.2013.12044.x.

5.

Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.

Scavone JL, Sterling RC, Van Bockstaele EJ.

Neuroscience. 2013 Sep 17;248:637-54. doi: 10.1016/j.neuroscience.2013.04.034. Epub 2013 Apr 24. Review.

6.

Association of cannabis use with opioid outcomes among opioid-dependent youth.

Hill KP, Bennett HE, Griffin ML, Connery HS, Fitzmaurice GM, Subramaniam G, Woody GE, Weiss RD.

Drug Alcohol Depend. 2013 Sep 1;132(1-2):342-5. doi: 10.1016/j.drugalcdep.2013.02.030. Epub 2013 Mar 22.

7.

Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice.

Ramesh D, Gamage TF, Vanuytsel T, Owens RA, Abdullah RA, Niphakis MJ, Shea-Donohue T, Cravatt BF, Lichtman AH.

Neuropsychopharmacology. 2013 May;38(6):1039-49. doi: 10.1038/npp.2012.269. Epub 2013 Jan 3.

8.

Clinical service desires of medical cannabis patients.

Janichek JL, Reiman A.

Harm Reduct J. 2012 Mar 13;9:12. doi: 10.1186/1477-7517-9-12.

9.

Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Mannelli P, Peindl KS, Lee T, Bhatia KS, Wu LT.

Curr Drug Abuse Rev. 2012 Mar;5(1):52-63. Review.

10.

Reinforcer-dependent enhancement of operant responding in opioid-withdrawn rats.

Cooper ZD, Shi YG, Woods JH.

Psychopharmacology (Berl). 2010 Oct;212(3):369-78. doi: 10.1007/s00213-010-1966-9. Epub 2010 Aug 5.

11.

Reduced cannabis use after low-dose naltrexone addition to opioid detoxification.

Mannelli P, Peindl K, Patkar AA, Wu LT, Pae CU, Gorelick DA.

J Clin Psychopharmacol. 2010 Aug;30(4):476-8. doi: 10.1097/JCP.0b013e3181e5c168. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk